Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript

Vaxart held a shareholder/analyst fireside chat on March 13, 2026 with CEO Steve Lo, CMO James Cummings, CSO Sean Tucker, CFO Jeroen Grasman and SVP/General Counsel Ed Berg. The session consisted mainly of introductions and standard forward-looking statement disclaimers referencing clinical, regulatory and financing risks; no material operational, financial or regulatory updates were announced. Treat the event as routine investor relations activity with minimal immediate impact on share price.

Analysis

Vaxart’s oral tablet platform remains a high optionality asset: if clinical data show meaningful mucosal immunity and transmission reduction, the product creates an economic wedge versus injectable boosters because it materially lowers cold-chain and administration costs. The second-order beneficiary list includes specialty contract manufacturers with oral-dosage expertise and distributors focused on low-resource markets — these partners could command stronger economics in any licensing deals, compressing Vaxart’s margin capture unless deal terms are negotiated tightly.

The principal near-term fragility is balance-sheet and regulatory path risk. A binary FDA decision or an adverse interim readout would compress valuation rapidly; conversely, a positive Phase result opens licensing conversations and non-dilutive capital but likely still requires 6–18 months to convert to firm partnerships. Watch CMC validation milestones closely: they are the single biggest practical hurdle to scaling tablets and will dictate the time-to-revenue even after efficacy is proven.

Competitive dynamics favor incumbents on deployment speed — mRNA and protein-platform boosters retain entrenched commercial channels — so Vaxart’s realistic commercial outcome is niche share in settings where logistics/cost trump brand trust. That reduces peak sales potential compared with broad booster winners but enhances takeover attractiveness for mid-sized vaccine players or CDMOs looking to bolt-on mucosal capability.

For traders, the story is classic optionality: binary upside with asymmetric downside driven by financing/delisting risk. Position-sizing should reflect that skew; the highest informational value events are regulatory interactions and CMC readouts over the next 6–12 months, which will reprice the equity and define partner leverage.

Key Decisions for Investors

• Tactical LEAP long: Buy small-sized long-dated VXRT call options (12–24 months) to capture upside from positive efficacy/CMC milestones. Position size 0.5–1.0% of portfolio; payoff asymmetry >3x if favorable readouts, but treat as total-loss risk — hedge with 25–35% of notional in protective puts if implied vol is rich.
• Hedged equity exposure: Initiate a 1–2% long VXRT equity position funded by a small short of a large-cap vaccine incumbent (e.g., PFE) to isolate platform-specific upside vs broad booster cyclicality. Hold 6–18 months; risk: financing/dilution can wipe equity value quickly — cap loss to 30% with stop-loss or protective puts.
• Downside insurance: Buy a 3–6 month VXRT put spread (long put, sell lower strike put) to limit cost while protecting against NASDAQ compliance/dilution outcomes. Cost ~low-mid single-digit % of notional; payout protects against >40–60% downside scenarios tied to regulatory/financing shocks.
• Event-driven catalyst play: Scale into or trim positions around CMC validation and any FDA meeting announcements (expected within 6–12 months). Increase exposure ahead of favorable readouts; take 50% profits within days of partner/license announcements to de-risk execution and non-dilutive capital formation.